Open-label, Multicenter, Single Arm, Phase II Study Assessing Treatment Patient Preference for New Deferasirox Formulation (Film-coated Tablet) Compared to the Reference Deferasirox Dispersible Tablet Formulation
Phase of Trial: Phase II
Latest Information Update: 10 Apr 2018
At a glance
- Drugs Deferasirox (Primary)
- Indications Thalassaemia
- Focus Therapeutic Use
- Acronyms Jupiter
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 03 Apr 2018 Planned End Date changed from 28 Dec 2020 to 27 Dec 2020.
- 03 Apr 2018 Planned primary completion date changed from 30 Apr 2018 to 27 Dec 2019.
- 30 Mar 2018 Planned End Date changed from 27 Oct 2020 to 28 Dec 2020.